Showing results (241-250 of 282) with videos related to
Sort By:
Pageof 29
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's MacroglobulinemiaRamón Garcia-Sanz, Marzia Varettoni, Cristina Jiménez, et al.American Journal of Hematology|March 10, 2025
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom MacroglobulinemiaJonas Paludo, Jithma P Abeykoon, Nirosha D Perera, et al.Blood Cancer Journal|February 2, 2020
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomasManit Munshi, Xia Liu, Jiaji G Chen, et al.British Journal of Haematology|December 15, 2015
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström MacroglobulinaemiaLian Xu, Zachary R Hunter, Nicholas Tsakmaklis, et al.Haematologica|November 12, 2020
A prognostic index predicting survival in transformed Waldenström macroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström MacroglobulinemiaSaurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, et al.The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.Blood Advances|March 7, 2022
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomasManit Munshi, Xia Liu, Amanda Kofides, et al.Clinical Lymphoma, Myeloma & Leukemia|November 30, 2021
POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter AnalysisArtur Jurczyszyn, Jorge J Castillo, Magdalena Olszewska-Szopa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple MyelomaTomas Jelinek, Renata Bezdekova, David Zihala, et al.Pageof 29